Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-01 · accession 0001415889-24-010139 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-04-03 | 2024-04-01 | JBIO | Verwijs Marinus | Chief TECHNICAL Off | S - Sale+OE | $29.19 | -5,300 | 0 | -100% | -$154.7K |
| D | 2024-04-03 | 2024-04-01 | JBIO | Verwijs Marinus | Chief TECHNICAL Off | M - OptEx | $14.59 | +5,300 | 5,300 | New | +$77.3K |
| D | 2024-04-03 | 2024-04-01 | JBIO | Verwijs Marinus | Chief TECHNICAL Off | M - OptEx | $0.00 | -5,300 | 79.4K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-01 | S | D | 3,796 | $28.87 | 1,504 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.475 to $29.24, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2024-04-01 | S | D | 1,504 | $30.00 | 0 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.65 to $30.45, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 3 | Common | Common Stock | 2024-04-01 | M | A | 5,300 | $14.59 | 5,300 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-04-01 | M | D | 5,300 | $0.00 | 79,400 | D | $14.59 · — to 2032-03-20 | 5,300 Common Stock | (F4) 25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. |